Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEMA-CORE study of pemafibrate in coronary plaque and renal function
jRCTs031210067Active, not recruiting
- Sponsor
- Kowa Company, Ltd.
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Randomised, open-label trial of pemafibrate in coronary arteriosclerosis, hypertriglyceridemia and dyslipidemia (2 arms), sponsored by Kowa Company, Ltd. Primary endpoints: Percent change in plaque volume and Change in LCBImax4mm. Started Jun 2021; status: active, not recruiting.
02
Drugs
pemafibrate
03
Conditions
coronary arteriosclerosishypertriglyceridemiadyslipidemia
Beyond the preview
Go deeper on jRCTs031210067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031210067.